PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
ARKG vs. GERM
Performance
Return for Risk
Drawdowns
Volatility
Dividends

ARKG vs. GERM

Last updated Jun 4, 2026

ARKG (ARK Genomic Revolution Multi-Sector ETF) and GERM (Amplify Treatments, Testing and Advancements ETF) are both Health & Biotech Equities funds. ARKG is actively managed, while GERM is passively managed. Over the past year, ARKG returned 53.35% vs 0.00% for GERM. ARKG charges 0.75%/yr vs 0.68%/yr for GERM.

Performance

ARKG vs. GERM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

ARKG

1D
-0.24%
1M
10.92%
YTD
17.09%
6M
10.02%
1Y
53.35%
3Y*
0.67%
5Y*
-15.72%
10Y*
7.22%

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
—
5Y*
—
10Y*
—
*Multi-year figures are annualized to reflect compound growth (CAGR)

ARKG vs. GERM - Yearly Performance Comparison

2026 (YTD)20252024
ARKG
ARK Genomic Revolution Multi-Sector ETF		17.09%23.04%-2.87%
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%

ARKG vs. GERM - Sectors Allocation Comparison

Sectors
ARKG
GERM

Healthcare

99.2%
99.3%

Financial Services

0.5%
0.4%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

ARKG
99.2%
GERM
99.3%

Financial Services

ARKG
0.5%
GERM
0.4%

Basic Materials

ARKG

-

GERM

-

Communication Services

ARKG

-

GERM

-

Consumer Cyclical

ARKG

-

GERM

-

Consumer Defensive

ARKG

-

GERM

-

Energy

ARKG

-

GERM

-

Industrials

ARKG

-

GERM

-

Real Estate

ARKG

-

GERM

-

Technology

ARKG

-

GERM

-

Utilities

ARKG

-

GERM

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

ARK Genomic Revolution Multi-Sector ETF

Amplify Treatments, Testing and Advancements ETF

Often compared with ARKG:
ARKG vs. ARKKARKG vs. XBIARKG vs. IBBARKG vs. GNOMARKG vs. IDNAARKG vs. ARKQARKG vs. ARKW
Often compared with GERM:
GERM vs. SBIOGERM vs. EQRRGERM vs. XBIGERM vs. GDOCGERM vs. XLVGERM vs. IHEGERM vs. MDEV

Return for Risk

ARKG vs. GERM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
ARKG
ARKG Risk / Return Rank: 3535
Overall Rank
ARKG Sharpe Ratio Rank: 3535
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 3737
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3232
Omega Ratio Rank
ARKG Calmar Ratio Rank: 3838
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3131
Martin Ratio Rank
GERM
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARKG vs. GERM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

ARKGGERMDifference
Sharpe ratioReturn per unit of total volatility
1.31

—

—

Sortino ratioReturn per unit of downside risk
1.99

—

—

Omega ratioGain probability vs. loss probability

1.22

—

—

Calmar ratioReturn relative to maximum drawdown

1.95

—

—

Martin ratioReturn relative to average drawdown

4.67

—

—

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARKG vs. GERM - Sharpe Ratio Comparison

Loading charts...

Sharpe Ratios by Period

ARKGGERMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.31

—

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.35

—

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.18

—

—

Sharpe Ratio (All Time)

Calculated using the full available price history

0.13

—

—

Drawdowns

ARKG vs. GERM - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for ARKG and GERM.

Loading charts...

Drawdown Indicators

ARKGGERMDifference

Max Drawdown

Largest peak-to-trough decline

-83.59%

0.00%

-83.59%

Max Drawdown (1Y)

Largest decline over 1 year

-27.51%

0.00%

-27.51%

Max Drawdown (3Y)

Largest decline over 3 years

-51.96%

—

—

Max Drawdown (5Y)

Largest decline over 5 years

-80.18%

—

—

Max Drawdown (10Y)

Largest decline over 10 years

-83.59%

—

—

Current Drawdown

Current decline from peak

-69.65%

0.00%

-69.65%

Average Drawdown

Average peak-to-trough decline

-35.87%

0.00%

-35.87%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.46%

0.00%

+11.46%

Volatility

ARKG vs. GERM - Volatility Comparison

ARK Genomic Revolution Multi-Sector ETF (ARKG) has a higher volatility of 11.90% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that ARKG's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

ARKGGERMDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.90%

0.00%

+11.90%

Volatility (6M)

Calculated over the trailing 6-month period

28.77%

0.00%

+28.77%

Volatility (1Y)

Calculated over the trailing 1-year period

41.12%

0.00%

+41.12%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

45.61%

0.00%

+45.61%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

41.12%

0.00%

+41.12%

ARKG vs. GERM - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is higher than GERM's 0.68% expense ratio.

Dividends

ARKG vs. GERM - Dividend Comparison

Neither ARKG nor GERM has paid dividends to shareholders.

PositionTTM202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF		0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

ARKG has higher volatility (11.90%) compared to GERM (0.00%). In terms of maximum drawdown, ARKG dropped -83.59% vs GERM's 0.00%.

On 1-year performance, ARKG leads with 53.35% vs 0.00% for GERM. On fees, GERM is cheaper at 0.68% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, ARKG has performed better with a 53.35% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

GERM is cheaper with a 0.68% expense ratio, compared with 0.75% for ARKG.

ARKG and GERM have nearly identical dividend yields, around 0.00%.

They also come from different issuers: ARK and Amplify. Their fees differ too: 0.75% for ARKG and 0.68% for GERM.

Portfolio Optimizer

Find the right allocation for ARKG and GERM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer